Last reviewed · How we verify
NCT06885645
First-In-Human Study in Participants With Advanced Solid Tumors
Phase 1 trial testing KH815 for injection in Advanced Solid Tumors in 30 participants. Not yet recruiting.
30 June 2027
Quick facts
| Lead sponsor | Chengdu Kanghong Biotech Co., Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | sequential |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 30 |
| Start date | 30 April 2025 |
| Primary completion | 30 June 2027 |
| Estimated completion | 31 December 2027 |
Drugs / interventions tested
- KH815 for injection — full drug profile →
Conditions studied
- Advanced Solid Tumors — all drugs for Advanced Solid Tumors →
Sponsor
Chengdu Kanghong Biotech Co., Ltd. — full company profile →
Who can join
Adults 18 to 75, any sex, with Advanced Solid Tumors. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Phase 1 Study of KH815 for Injection to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Anti-tumor Activity in Patients with Advanced Solid Tumors
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The next frontier in antibody-drug conjugates: challenges and opportunities in cancer and autoimmune therapy.
Zhou M, Huang Z, Ma Z, Chen J, et al · · 2025 · cited 8× · PMID 40843358 · DOI 10.20517/cdr.2025.49 -
The evolving landscape of antibody-drug conjugates (ADCs) for treatment of prostate cancer.
Lin C, Hadfield MJ, Santopietro A, Lagos G, et al · · 2025 · cited 1× · PMID 41238753 · DOI 10.1038/s41698-025-01131-0 -
Clinical Pharmacology and Translational Science Considerations in the Development of Dual-Payload Antibody Drug Conjugates.
Ravenstijn P, Kakinuma T, Hamed S, Kadokura T, et al · · 2026 · PMID 42089685 · DOI 10.1111/cts.70569
Verify or expand the search:
- PubMed search for NCT06885645
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Advanced Solid Tumors
Currently open trials in the same condition.
- NCT07504445 — Clinical Study on the Efficacy and Safety of CAR-DC in the Treatment of Advanced Solid Tumors · EARLY_PHASE1 · recruiting
- NCT07589530 — Phase 1/2 Study of EB-NK-301 (Allogeneic TROP2-CAR NK Cells) in Advanced TROP2-Expressing Solid Tumors · Phase 1, PHASE2 · recruiting
- NCT07360314 — Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors · Phase 1 · recruiting
- NCT07414316 — A Single-Arm, Open-Label Clinical Study GK01 Cell Injection in Subjects With Advanced Solid Tumors. · EARLY_PHASE1 · recruiting
- NCT07222969 — A Clinical Study to Evaluate the Safety of VIB305 in Patients With Advanced Solid Tumors · Phase 1, PHASE2 · recruiting
Other Chengdu Kanghong Biotech Co., Ltd. trials
Trials by the same sponsor.
- NCT04990271 — A Clinical Study on the Efficacy and Safety of VEC Intravenous Chemotherapy Combined With Conbercept Intravitreal Inject · Phase 2 · unknown
- NCT04555304 — Phase 2 Study of KH903 in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma As Second-Line Ther · Phase 2 · unknown
- NCT03630952 — Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-2) · Phase 3 · terminated
- NCT03577899 — Efficacy and Safety Trial of Conbercept Intravitreal Injection for Neovascular AMD (PANDA-1) · Phase 3 · terminated
- NCT03244657 — Phase IV Clinical Trial (STAR Study) Extension Study of Conbercept Ophthalmic Injection for Treatment of Polypoid Choroi · Phase 4 · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06885645 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Chengdu Kanghong Biotech Co., Ltd.
- Last refreshed: 3 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06885645.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing